Abstract: Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.
Type:
Grant
Filed:
May 17, 2021
Date of Patent:
July 18, 2023
Assignee:
AVIXGEN INC.
Inventors:
Young Myeong Kim, Yi Yong Baek, Won Jin Park, Jeong Hun Kim, Dong Hyun Jo
Abstract: The present invention pertains to: a botulinum toxin, epithelial cell growth factor, or hexapeptide fusion protein bound to skin tissues and cell-permeable peptides, or an epithelial cell growth factor mixed with skin tissues and cell-permeable peptides; and a composition comprising same. The fusion protein or the epithelial cell growth factor mixed with cell-permeable peptides has increased cell permeability compared to protein by itself, and is thus useful for improving the condition of skin, treating wrinkles, relieving muscle tension, and treating wounds.
Type:
Grant
Filed:
June 7, 2019
Date of Patent:
January 10, 2023
Assignee:
AVIXGEN INC.
Inventors:
Yi Yong Baek, Woo Ri Shin, Si Eun Park, Jun Sub Choi, Hye Cheong Koo
Abstract: The present invention relates to a peptide for inhibiting skin inflammation and a pharmaceutical composition and a cosmetic composition for preventing or treating skin inflammation including the same. Since the peptide, pharmaceutical composition and cosmetic composition are effective for improving symptoms of skin inflammation caused by atopic dermatitis and the like, they are useful for preventing, improving or treating skin inflammation.
Type:
Grant
Filed:
December 17, 2018
Date of Patent:
December 28, 2021
Assignee:
AVIXGEN Inc.
Inventors:
Yi Yong Baek, Jun Sub Choi, Hye Cheong Koo
Abstract: The present invention relates to a cell membrane penetrating peptide and an intracellular delivery carrier including the same. The intracellular delivery carrier of the present invention has an advantage of efficiently transferring substances into cells even at a low concentration thereof compared with the existing cell membrane penetrating peptide derived from the virus.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating AIDS, comprising a rhodanine derivative and a nucleoside reverse transcriptase inhibitor. A complex composition of the present invention exhibits a synergistic effect in terms of anti-HIV activity as compared with a case where each of the compounds is used as a single drug. Thus, the composition provides sufficient anti-HIV activity and exhibits an excellent effect of decreasing side effects such as toxicity even in a case where each compound is administered in a small amount. Accordingly, the present invention is expected to greatly contribute to treatment of AIDS patients.
Type:
Grant
Filed:
September 17, 2020
Date of Patent:
October 12, 2021
Assignee:
AVIXGEN INC.
Inventors:
Min Jung Kim, Jun Sub Choi, Hye Cheong Koo, Yi Yong Baek
Abstract: Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.
Type:
Application
Filed:
May 17, 2021
Publication date:
September 23, 2021
Applicant:
AVIXGEN INC.
Inventors:
Young Myeong KIM, Yi Yong BAEK, Won Jin PARK, Jeong Hun KIM, Dong Hyun JO
Abstract: The present invention relates to a composition comprising a fusion protein of a cell-penetrating peptide and Retinal Pigment Epithelium-specific 65 kDa (RPE65) as an effective ingredient. With RPE65 increased in cell penetrability, the composition can be advantageously used for treatment of Leber's congenital amaurosis.
Type:
Application
Filed:
June 7, 2019
Publication date:
August 19, 2021
Applicant:
Avixgen Inc.
Inventors:
Woo Ri SHIN, Yi Yong BAEK, Jun Sub CHOI, Hye Cheong KOO
Abstract: The present invention pertains to: a botulinum toxin, epithelial cell growth factor, or hexapeptide fusion protein bound to skin tissues and cell-permeable peptides, or an epithelial cell growth factor mixed with skin tissues and cell-permeable peptides; and a composition comprising same. The fusion protein or the epithelial cell growth factor mixed with cell-permeable peptides has increased cell permeability compared to protein by itself, and is thus useful for improving the condition of skin, treating wrinkles, relieving muscle tension, and treating wounds.
Type:
Application
Filed:
June 7, 2019
Publication date:
August 19, 2021
Applicant:
Avixgen Inc.
Inventors:
Yi Yong BAEK, Woo Ri SHIN, Si Eun PARK, Jun Sub CHOI, Hye Cheong KOO
Abstract: The present disclosure relates to the use of a rhodanine derivative in the prevention, amelioration or treatment of osteoarthritis. The rhodanine derivative according to the present disclosure has excellent effects of rescuing the loss of the cartilage matrix and alleviating synovitis, and thus may be effectively used for the prevention, amelioration or treatment of osteoarthritis.
Abstract: Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.
Type:
Grant
Filed:
July 5, 2016
Date of Patent:
June 22, 2021
Assignee:
AVIXGEN INC.
Inventors:
Young Myeong Kim, Yi Yong Baek, Won Jin Park, Jeong Hun Kim, Dong Hyun Jo
Abstract: The present invention relates to a composition comprising, as an active ingredient, a fusion protein of a cell penetrating peptide and adenosine deaminase, wherein the composition can be efficiently used for treating severe complex immunodeficiency due to the increased cell permeability of adenosine deaminase.
Type:
Application
Filed:
June 7, 2019
Publication date:
April 15, 2021
Applicant:
Avixgen Inc.
Inventors:
Eun Hye JI, Geon Young AHN, Yi Yong BAEK, Jun Sub CHOI, Hye Cheong KOO
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating AIDS, comprising a rhodanine derivative and a nucleoside reverse transcriptase inhibitor. A complex composition of the present invention exhibits a synergistic effect in terms of anti-HIV activity as compared with a case where each of the compounds is used as a single drug. Thus, the composition provides sufficient anti-HIV activity and exhibits an excellent effect of decreasing side effects such as toxicity even in a case where each compound is administered in a small amount. Accordingly, the present invention is expected to greatly contribute to treatment of AIDS patients.
Type:
Application
Filed:
September 17, 2020
Publication date:
January 7, 2021
Applicant:
AVIXGEN INC.
Inventors:
Min Jung KIM, Jun Sub Choi, Hye Cheong Koo, Yi Yong Baek
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating AIDS, comprising a rhodanine derivative and a nucleoside reverse transcriptase inhibitor. A complex composition of the present invention exhibits a synergistic effect in terms of anti-HIV activity as compared with a case where each of the compounds is used as a single drug. Thus, the composition provides sufficient anti-HIV activity and exhibits an excellent effect of decreasing side effects such as toxicity even in a case where each compound is administered in a small amount. Accordingly, the present invention is expected to greatly contribute to treatment of AIDS patients.
Type:
Grant
Filed:
August 29, 2019
Date of Patent:
November 3, 2020
Assignee:
AVIXGEN INC.
Inventors:
Min Jung Kim, Jun Sub Choi, Hye Cheong Koo, Yi Yong Baek
Abstract: Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.
Type:
Application
Filed:
July 5, 2016
Publication date:
October 17, 2019
Applicant:
AVIXGEN INC.
Inventors:
Young Myeong KIM, Yi Yong BAEK, Won Jin PARK, Jeong Hun KIM, Dong Hyun JO
Abstract: The present invention relates to a cell membrane penetrating peptide and an intracellular delivery carrier including the same. The intracellular delivery carrier of the present invention has an advantage of efficiently transferring substances into cells even at a low concentration thereof compared with the existing cell membrane penetrating peptide derived from the virus.
Abstract: The present invention relates to a composition for preventing or treating dry eye syndrome or eye diseases caused by dry dyes, containing imatinib as an active ingredient and, more specifically, to an eye bath lotion for preventing or treating dry eye syndrome or eye diseases associated with dry eye syndrome, containing imatinib an active ingredient. Imatinib of the present invention effectively protects the corneal epithelia and inhibits the degeneration thereof, thereby being usable for a use of alleviating or treating dry eye syndrome or eye diseases associated with dry eye syndrome.
Abstract: The present invention relates to a novel use of the HIV NC protein, and more particularly, it is relates to a pharmaceutical composition for preventing and treating AIDS having a polypeptide comprising HIV NC protein as an active component and the method of inhibiting HIV proliferation by using the polypeptide. The polypeptide comprising HIV NC protein of the present invention, when it is overexpressed, has the effect on inhibiting HIV proliferation. Accordingly, the present invention provides not only the novel means of inhibition of HIV proliferation, but also the novel method for preventing and treating AIDS.
Abstract: The present invention relates to a composition for preventing or treating dry eye syndrome or eye diseases caused by dry dyes, containing imatinib as an active ingredient and, more specifically, to an eye bath lotion for preventing or treating dry eye syndrome or eye diseases associated with dry eye syndrome, containing imatinib an active ingredient. Imatinib of the present invention effectively protects the corneal epithelia and inhibits the degeneration thereof, thereby being usable for a use of alleviating or treating dry eye syndrome or eye diseases associated with dry eye syndrome.
Abstract: Provided are a tetrapeptide for inhibiting VEGF-induced angiogenesis and a use thereof, and particularly, provided is a peptide having the amino acid sequence of R-X1-X2-E (wherein X1 is leucine (L), isoleucine (I) or valine (V), and X2 is tyrosine (Y) or phenylalanine (F)) for inhibiting angiogenesis, or preventing, improving or treating cancer. This research was supported by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea, in 2011 and 2013 [NRF-2011-0028790 and 2013M3A9B6046563]. The tetrapeptide may effectively inhibit VEGF-induced angiogenesis or growth of cancer cells without a risk of side effects, and therefore may be expected to exhibit an excellent anticancer effect.
Type:
Grant
Filed:
July 28, 2016
Date of Patent:
May 15, 2018
Assignee:
AVIXGEN INC.
Inventors:
Young Myeong Kim, Yi Yong Baek, Dong Keon Lee, Jun-Sub Choi, Min Jung Kim, Hye Cheong Koo
Abstract: The present invention relates to a vector for expressing an NC protein of HIV and a method for producing an NC protein using the same. More particularly, the present invention relates to a vector for expressing an NC protein of HIV, in which an intron sequence and an mRNA stability element in the downstream of NC gene are sequentially linked, and a method for producing an NC protein using the same. The vector for expressing an NC protein of HIV of the present invention, in which an intron sequence and an mRNA stability element in the downstream of NC gene are sequentially linked, can express a wild type NC protein in animal cells, and has an effect of improving the expression efficiency, as compared to a known art.